This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

Start Date01 Mar 2029

Sponsor / Collaborator

Womack Army Medical Center

[+1]

NCT06839989

/ Not yet recruitingPhase 2IIT

The Mpox Biology, Outcome, Transmission and Epidemiology Project - HIV Immunization and Vaccination Against Mpox EXposure Trial

This is an open-label, phase 2, immunogenicity and safety trial of the MVA-BN vaccine for the prevention of mpox in adults living with HIV with different level of CD4 counts in Kinshasa, DRC.
The study team aims to investigate whether the administration of 2 standard subcutaneous doses of the Modified Vaccinia Ankara of Bavarian Nordic (MVA-BN) vaccine given 28 days apart, is immunogenic and safe when administered to People Living with HIV (PLHIV) with different levels of CD4 counts in the Democratic Republic of the Congo (DRC).
Enrollment will be stratified according to three different subgroups based on CD4 counts assessed during visit 1A: <200 cells/µL; 200 to 499 cells/µL; ≥ 500 cells/µL. A total of 600 participants will be included in the trial, with 200 participants per subgroup.
All participants will be invited to 6 trial visits over a period of 7 months.
This study will take place in cooperation with the National Programme for the Fight against AIDS (PNLS), the 'Programme Elargi de Vaccination (PEV)' and the 'Institut National de Santé Publique (INSP)'. As part of the response to the current mpox epidemic in DRC, a large cohort of about 10,000 individuals living in Kinshasa will be vaccinated in this program. Vaccination will take place in the Centre Hospitalier Kabinda (CHK) and the Pakadjuma Health Centre. All people living with HIV (PLHIV) with the intention to be vaccinated in the CHK, will be asked for their willingness to participate in the MBOTE-HIVAX clinical trial until the sample size of 600 participants needed for this clinical trial is reached.

Start Date01 May 2025

Sponsor / Collaborator

MSF Medecins Sans Frontieres

NCT06844500

/ Not yet recruitingPhase 3IIT

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection. The study will be conducted in Boende, Tshuapa Province, DRC.
A total of 359 maternal participants, aged 16 to 35 and in their second or third trimester of pregnancy, will be enrolled. Participants will be randomly assigned to receive two subcutaneous doses of the MVA-BN vaccine, given 28 days apart, either during pregnancy (Maternal Group 1) or within 72 hours after delivery (Maternal Group 2). Additionally, pregnant women in any trimester who have been recently exposed to a confirmed mpox case will be enrolled in the post-exposure prophylaxis (PEP) arm (Maternal Group 3), receiving the vaccine as soon as possible after exposure-ideally within four days but up to 14 days if they remain asymptomatic.
The study will evaluate the safety, reactogenicity, and immune responses of vaccinated pregnant women compared to healthy adults in the POX-MVA-045 study (NCT06549530) through non-inferiority analyses. Participants will be monitored for immunogenicity and safety for 13 months post-delivery, while neonates will be observed for safety over the same period. The trial will also compare outcomes between women vaccinated during pregnancy and those vaccinated postpartum, assess the transfer of maternal immunity to neonates, and explore correlations between maternal antibody levels in serum and breast milk.
This study seeks to provide strong evidence supporting the safety and immunogenicity of the MVA-BN mpox vaccine in pregnancy, contributing to global public health efforts to protect at-risk women and their infants in mpox-endemic regions.

Start Date31 Mar 2025

Sponsor / Collaborator

University of Antwerp

[+4]

100 Clinical Results associated with Smallpox vaccine(Bavarian Nordic A/S)

100 Translational Medicine associated with Smallpox vaccine(Bavarian Nordic A/S)

100 Patents (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

1,023

Literatures (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

31 Dec 2025·Virulence

Mpox: Global epidemic situation and countermeasures

Review

Author: Luo, Yinghua ; Jin, Chenghao ; Hou, Wenshuang ; Tang, Yanjun ; Wu, Nan ; Liu, Yanzhi ; Quan, Quan

Mpox, is a zoonotic disease caused by the monkeypox virus and is primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance to the smallpox virus is declining, increasing the risk of infection with mpox and other viruses. On 14 August 2024, the World Health Organization announced that the spread of mpox constituted a public health emergency of international concern. Mpox's transmission routes and symptoms are complex and pose new challenges to global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, and genetically engineered vaccines) and antiviral drugs (such as tecovirimat, brincidofovir, cidofovir, and varicella immunoglobulin intravenous injection) have been developed and marketed to prevent and control this disease. This review aims to introduce the epidemic situation, epidemiological characteristics, physiological and pathological characteristics, and preventive measures for mpox in detail, to provide a scientific basis for the prevention and control of mpox viruses worldwide.

01 Apr 2025·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Short-term evolution of Mpox-specific IgG and neutralizing antibodies among individuals undergoing MVA-BN vaccination

Article

Author: Chen, Kai-Hsiang ; Huang, Yu-Shan ; Chao, Tai-Ling ; Chen, Ling-Ya ; Li, Guei-Chi ; Chen, Yi-Chun ; Liu, Wen-Chun ; Liu, Wang-Da ; Chang, Hsi-Yen ; Chang, Sui-Yuan ; Yao, Yi ; Lin, Chia-Yi ; Chang, Lan-Hsin ; Wang, Jann-Tay ; Hung, Chien-Ching ; Chen, Yi-Ting ; Luo, Yu-Zhen ; Wu, Cheng-Hsin ; Hsu, Wei-Ting ; Chang, Shih-Chung ; Su, Yi-Ching ; Sun, Hsin-Yun ; Sheng, Wang-Huei ; Huang, Chun-Fu ; Hsieh, Szu-Min ; Lin, Kuan-Yin ; Wu, Pei-Ying ; Lin, Chi-Ying ; Chuang, Yu-Chung

OBJECTIVES:

The data on immune responses of individuals undergoing modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination are scarce. We aimed to compare Mpox virus-specific antibody and neutralizing antibody responses among people with and those without HIV receiving MVA-BN vaccines.

METHODS:

This prospective study enrolled participants undergoing two-dose MVA-BN vaccination to investigate seroresponses after vaccination. Blood samples were collected before and after each dose of vaccination for determinations of anti-A29 and anti-H3 IgG. Neutralization tests were conducted for samples tested positive for both anti-A29 and anti-H3 IgG.

RESULTS:

Overall, 441 participants undergoing two-dose MVA-BN vaccination were enrolled. Seroconversion for anti-A29 and anti-H3 IgG, respectively, after the second dose of vaccination was 18.2% and 61.2%, 10.9% and 65.0%, and 51.6% and 90.6% among people with HIV, people without HIV, and those who had had smallpox vaccination previously, respectively. About 20% of the participants with seroconversion lost seroresponses after a 7-month period of observation. None of the serum samples from vaccinated participants demonstrated neutralizing ability.

CONCLUSIONS:

Participants with previous smallpox vaccination had higher and more sustained antibody responses after receiving two doses of MVA-BN vaccines than those who had not undergone smallpox vaccination. More studies are warranted to assess the seroresponses to booster MVA-BN vaccination for vaccine nonresponders or those having lost seroresponses.

01 Mar 2025·Lancet Microbe

Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK

Article

Author: Byard, Nicholas ; Crook, Alison ; Jenkin, Daniel ; Thomas, Merin ; Borthwick, Nicola ; Baker, Megan ; Hayes, Peter J ; Watson, Marion ; Wee, Edmund G-T ; Luciw, Michael ; Cicconi, Paola ; Quaddy, Jack ; Conway, Oliver ; Poulton, Ian ; Larkworthy, Colin ; Baines, Andrea ; Akis Yildirim, Belkis M ; Platt, Abigail ; Fernandez, Natalia ; Hanke, Tomáš ; Glaze, Molly

BACKGROUND:

An HIV-1 vaccine is long overdue. Although vaccine research focuses on the induction of broadly neutralising antibodies, challenging infections such as HIV-1 could require parallel induction of protective T cells. It is important to recognise that not all T cells contribute to protection equally. Previously, we developed a T-cell immunogen-based bivalent mosaic vaccine, HIVconsvX, delivered by vaccine vectors ChAdOx1 and modified vaccinia Ankara. In this study, we tested the HIVconsvX vaccine regimen for the first time in humans. Other ongoing trials will assess the contribution of the vaccine-induced killer T cells to the control of HIV-1.

METHODS:

HIV-CORE 005.2 was an open-label, dose-escalation, first-in-human, phase 1 trial done at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK. Eligible participants were healthy volunteers aged 18-65 years living without HIV-1 and at a low likelihood of acquiring it. Because it was the first administration of ChAdOx1.tHIVconsv1 (C1) to humans, participants were assigned stepwise to two groups. Volunteer group 1 received a low dose of C1 on enrolment. Following a satisfactory safety review 7 days after vaccination, volunteer group 2 received a full dose of C1 boosted by vaccines MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4) 4 weeks later in regimen C1-M3M4 and were followed up until day 140. Focusing on the full vaccine doses in group 2, the primary outcome was the local and systemic safety of the vaccine. The secondary outcome was the frequency and breadth of epitope recognition by vaccine-induced T cells determined by IFN-γ ELISPOT assay using peripheral blood mononuclear cells (PBMC) at peak (1 and 2 weeks after the M3M4 boost) and at the end of the study, assessed against volunteer's pre-vaccination levels. The HIV-CORE 005.2 trial is registered at ClinicalTrials.gov (NCT04586673) and is closed.

FINDINGS:

Between July 3, 2021, and Aug 3, 2022, 13 participants were recruited and assigned to group 1 (n=3) and group 2 (n=10). Low-dose C1 was safe and well tolerated in group 1, and all three vaccine components were well tolerated in volunteer group 2. There were no serious adverse events. Local and systemic reactogenicities were consistent with intramuscular needle administration of immunogenic substances. All volunteers responded, and their vaccine-elicited T-cell frequencies peaked at a median of 4433 (IQR 2750-5820) IFN-γ spot-forming units per 10⁶ PBMC and recognised a median of 9 (IQR 9-10) peptide pools out of 10, indicating that the responses were broadly specific and each vaccine recipient targeted at least nine epitopes on HIV-1. These frequencies were 7·4 times lower by day 140 (ie, 3 months later). T cells proliferated upon antigen re-exposure and displayed multiple effector functions, recognised variant epitopes, and inhibited HIV-1 from the four major global clades A, B, C, and D.

INTERPRETATION:

These results inform and support a programme of clinical evaluations of the HIVconsvX T-cell vaccines together with other cutting-edge tools for HIV-1 cure and prevention such as latency reactivating agents, passively infused combinations of broadly neutralising antibodies, and active Env-based vaccines or immunomodulators.

FUNDING:

EU Horizon 2020 Research and Innovation programme, Medical Research Council and Foreign Commonwealth and Development Office Concordat agreement, European and Developing Countries Clinical Trials Partnership, National Institute for Health Research Oxford Biomedical Research Centre, and IAVI.

270

News (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

03 Mar 2025

·www.pharmaceutical-technology.com

EC approves Bavarian Nordic’s chikungunya vaccine marketing

The vaccine’s launch by the company in the main European markets is anticipated in the first half of 2025. Credit: Pormezz/Shutterstock. The European Commission (EC) has authorised the marketing of Bavarian Nordic’s Vimkunya – the first chikungunya vaccine approved in Europe for individuals as young as 12 years old. Vimkunya is a virus-like particle (VLP) single-dose vaccine tailored for active immunisation to prevent disease caused by the chikungunya virus. The authorisation is valid in all European Union member states and also in Liechtenstein, Norway and Iceland. The announcement follows US Food and Drug Administration (FDA) approval in February 2025. A marketing authorisation application was submitted by the company to the UK’s Medicines and Healthcare products Regulatory Agency, with UK approval anticipated in the first half of 2025. Bavarian Nordic CEO and president Paul Chaplin said: “We are highly encouraged by the European Commission’s accelerated decision to approve our chikungunya vaccine in Europe, which offers a differentiated profile for travellers, including those as young as 12 years. “As we expand our presence across Europe, this vaccine will help to further consolidate our leading position in travel vaccines, and we look forward to making the vaccine available in key markets during the first half of 2025.” The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the vaccine in January 2025, based on two Phase III clinical trial outcomes. These trials enrolled 3,500 healthy participants aged 12 and above. It demonstrated that the vaccine induced neutralising antibodies in up to 97.8% of vaccinated people within 21 days post-vaccination and showed a quick immune response from the first week. The vaccine’s mechanism of action involves inducing neutralising antibodies against chikungunya virus proteins, potentially offering protection from infection. In December 2024, the company signed a licence and manufacturing agreement with the Serum Institute of India for MVA-BN.

Phase 3Drug ApprovalVaccineClinical Result

20 Jan 2025

·www.globenewswire.com

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation. Since initiation of the program, the following transactions have been made: Number of sharesAverage purchase price, DKKTransaction value, DKKJanuary 9, 202547,000205.209,644,400January 10, 202550,000204.0710,203,500January 13, 202553,000196.5010,414,500January 14, 202555,000196.3710,800,350January 15, 202553,000191.7110,160,630January 16, 202550,000195.539,776,500January 17, 202550,000196.139,806,500Accumulated under the program358,000197.7870,806,380 The details for each transaction made under the share repurchase program are published on bavarian-nordic.com. Following these transactions, Bavarian Nordic holds a total of 642,235 treasury shares, corresponding to 0.81 % of the Company’s share capital. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: + 45 53 88 06 03 Company Announcement no. 02 / 2025 Attachments 2025-02-en 2025-02-appendix-en

Vaccine

09 Jan 2025

·www.globenewswire.com

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024. The decision to launch the program is driven by a better-than-expected performance and improved visibility pertaining to the Company’s Travel Health business, with synergies from a number of recent and near-term expected events as described in the December 11 announcement. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure and meeting the long-term obligations relating to the Company’s share-based incentive programs for the Board of Directors and Executive Management. The share buy-back program is initiated pursuant to the authorization granted at the annual general meeting on April 16, 2024, and in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation. Bavarian Nordic has appointed Danske Bank A/S as lead manager to execute the share buy-back in accordance with the terms of the program and with authorization to make trading decisions independently and without influence of Bavarian Nordic. Terms of the program The share buy-back program will commence on January 9, 2025, and will be completed by February 5, 2025, at the latest.Shares of up to a maximum aggregate purchase price of DKK 150 million may be repurchased. A maximum of 1,500,000 shares will be repurchased within the duration of the program.The maximum number of shares, which can be purchased on any single trading day, may not exceed 25% of the average daily trading volume of Bavarian Nordic shares traded on Nasdaq Copenhagen during the preceding 20 trading days before the trading day.The shares may not be purchased at a price exceeding the higher of the price of the last independent trade, or the highest independent purchase bid on Nasdaq Copenhagen. Details of transactions under the program will be published weekly after commencement and at completion of the program. Prior to the initiation of this program, Bavarian Nordic held 284,235 treasury shares, corresponding to 0.36 % of the Company’s share capital. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: + 45 53 88 06 03 Company Announcement no. 01 / 2025 Attachment 2025-01-en

Vaccine

100 Deals associated with Smallpox vaccine(Bavarian Nordic A/S)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Smallpox vaccine(Bavarian Nordic A/S)	J07BX	DB15483

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Monkeypox	European Union	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Iceland	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Norway	Bavarian Nordic A/S	31 Jul 2013
Smallpox	European Union	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Iceland	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Norway	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	European Union	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Iceland	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Norway	Bavarian Nordic A/S	31 Jul 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	Republic of the Congo	Bavarian Nordic A/S	31 Mar 2025
Dermatitis, Atopic	Phase 2	United States	Bavarian Nordic A/S	01 Jul 2006
Dermatitis, Atopic	Phase 2	Mexico	Bavarian Nordic A/S	01 Jul 2006
HIV Infections	Phase 2	United States	Bavarian Nordic A/S	01 Jun 2006
HIV Infections	Phase 2	Puerto Rico	Bavarian Nordic A/S	01 Jun 2006
Rhinitis, Allergic, Seasonal	Phase 1	Germany	Bavarian Nordic A/S	01 Apr 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05512949 (NEWS) Manual	Phase 2	Monkeypox	229	MVA-BN (aged between 12 and 17 years)	cqutcgsros(hgofsrlqnp) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. miikosmrvt (jotbcgdjvu ) View more	Positive	17 Oct 2024
Literature Manual	Not Applicable	Monkeypox	45	MVA-BN 2 doses	yxgklegygl(cxxbetrdjr) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months yvfvsocana (weupdfilco )	Negative	03 Oct 2024
				MVA-BN 1 doses
NCT05740982 (NEWS) Manual	Phase 2	Hemorrhagic Fever, Ebola	526	IMVANEX (adolescents 12-17 years of age)	ndzqwtpodg(wvzrgeulae) = a similar safety profile between both age groups wfntmrqmkv (txbbcwvcsf ) View more	Positive	19 Sep 2024
				IMVANEX (adults aged 18 years and older)
NCT05512949 (CTgov)	Phase 2	Monkeypox	229	MVA-BN (2 x 10^7 ID MVA-BN)	frtaqcjaho(wuilfhtbkk) = sududvumyp fephfssbvc (egktrzzwsn, zlzcuyaeaj - eqavuyomti) View more	-	09 Jan 2024
				MVA-BN (1 x 10^7 ID MVA-BN)	frtaqcjaho(wuilfhtbkk) = hwnfzxgkhp fephfssbvc (egktrzzwsn, sbkasjbnjj - zqrgmosnvi) View more
NCT03699124 (Pubmed) Manual	Phase 3	-	1,129	MVA-BN	vdaxbnktuq(kekjoizuut) = pcsxjoakis nurjaqhvmb (ygmvooitlm ) View more	Positive	29 Nov 2022
NCT03699124 (CTgov)	Phase 3	Smallpox	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	vmchicogdp(etpfkvhuqn) = orzudpbfog grbfxrnccd (uhwsmmhxio, ybsypezvyn - dzsmgscaaq) View more	-	27 May 2021
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	vmchicogdp(etpfkvhuqn) = ipwknhvcpr grbfxrnccd (uhwsmmhxio, ayoahcirsk - dhsiqjqpew) View more
NCT01668537 (CTgov)	Phase 2	Smallpox	651	LF (LF Formulation)	uihsqcokfx(jksflbdhxh) = qumrvjglgw lyvtrbgoel (ytrmlicwpi, nsycfjdtob - dccmnlqfni) View more	-	12 Oct 2020
				MVA-BN (FD Formulation)	uihsqcokfx(jksflbdhxh) = pxrddlwxat lyvtrbgoel (ytrmlicwpi, wjycativke - tbunetdwuy) View more
NCT03472014 (CTgov)	Phase 4	-	22	MVA-BN	pybvepinpx = zbzyycznai iogxwdfmav (vyuyyxlcin, hikyfgznks - uklhrtgnje) View more	-	19 Aug 2020
NCT01913353 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	Smallpox	433	modified vaccinia Ankara+ACAM2000	eykpkwsdyq(umvyxwpbzt): RO = 97.9 (95% CI, 96.6 - 98.3) View more	Superior	14 Nov 2019
				ACAM2000
NCT00686582 (CTgov)	Phase 2	Smallpox	304	IMVAMUNE (Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose)	gjspvkahyr = wuzudvgihi quivlnccnq (bkodzbkqtf, jyaispzuiu - ggykzewmvr) View more	-	18 Feb 2019
				IMVAMUNE (Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose)	gjspvkahyr = xrapqybcsk quivlnccnq (bkodzbkqtf, rpvmdddjol - flknwftfnw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Smallpox vaccine(Bavarian Nordic A/S)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation